e-learning
resources
Berlin 2001
Tuesday 25.09.2001
Small cell lung cancer therapy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Myocardial infarction (MI) as a cause of death in patients treated for small cell lung cancer (SCLC)
P. Remiszewski, J. Slodkowska, B. Roszkowska, E. Decker, M. Marzinek, E. Rowiñska-Zakrzewska (Warsaw, Poland)
Source:
Annual Congress 2001 - Small cell lung cancer therapy
Session:
Small cell lung cancer therapy
Session type:
Thematic Poster Session
Number:
2698
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Remiszewski, J. Slodkowska, B. Roszkowska, E. Decker, M. Marzinek, E. Rowiñska-Zakrzewska (Warsaw, Poland). Myocardial infarction (MI) as a cause of death in patients treated for small cell lung cancer (SCLC). Eur Respir J 2001; 16: Suppl. 31, 2698
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Two-stage treatment of non-small cell lung cancer (NSCLC) in patients with severe coronary heart disease.
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
Use of Bode index (BI) in patients with COPD undergoing inpatient pulmonary rehabilitation (IPR) after lung resection (LR) for non small cell lung cancer (NSCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 70s
Year: 2006
Causes of death in inoperable non small cell lung cancer (NSCLC)-retrospective study
Source: Eur Respir J 2004; 24: Suppl. 48, 76s
Year: 2004
Small cell lung cancer in patients with elderly
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC)
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019
How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Cancer recurrence in surgically treated non small cell lung cancer (NSCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 755s
Year: 2006
Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005
Tissue factor induced tumor vascular infarction in lung cancer
Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Year: 2018
C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002
European treatment guidelines: small cell lung cancer (SCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Causes of death in patients operated for lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 173s
Year: 2005
Small cell lung cancer (SCLC) in Norway. A population-based study
Source: Annual Congress 2008 - Actual challenges in thoracic surgery
Year: 2008
LATE-BREAKING ABSTRACT: A mRNA signature predicts outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V): A ELCWP prospective study
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC)
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Myocardial infarction, heart failure and mortality in patients with COPD in primary care.
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation
Source: Annual Congress 2011 - Quality management for lung cancer patients
Year: 2011
Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept